Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

pharmiweb.com today archive

1866 PWToday Stories

MedDay Boosts its Research Capabilities with Profilomic Acquisition

07 Mar 17

MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces it has boosted its research platform by acquiring the health division of Profilomic SA (“Profilomic”), an innovative company formed out of Commissariat à l’Energie Atomique (CEA) in 2010. Today’s acquisition will allow MedDay to significantly strengthen its existing metabolomics research platform, SPECMET, with the aim of expanding its pipeline of neurological disorder therapies in areas of high unmet medical need.

 

Under the terms of the acquisition, MedDay has acquired all of the health-related assets from Profilomic, including an extensive database and laboratory equipment alongside a team of highly skilled scientists with world-class expertise in the field of metabolomics and lipidomics. SPECMET was developed in collaboration with the CEA and this acquisition will further strengthen the existing partnership and the research platform will remain close to its scientific origins at the CEA. Financial terms are undisclosed.

 

The MedDay SPECMET platform supports the discovery of additional pipeline assets by identifying new therapeutic targets through metabolomics analysis of cerebrospinal fluid (CSF). SPECMET screens CSF from patients with various Central Nervous System (CNS) disorders to identify the disrupted metabolic pathways. Compounds that are known to affect these metabolic pathways are then identified and further developed. New data from the platform has shown that this approach is able to identify metabolic pathway alterations in some neurological disorders where no suitable therapy is currently available1. Based on the metabolic signatures identified by SPECMET in some neurological conditions, development targets can progress into preclinical studies and, if successful, have the potential to move rapidly into clinical development. 

 

Commenting on the acquisition, Frédéric Sedel, Chief Executive Officer of MedDay, said: “Tackling unmet medical need in central nervous system disorders by acting on brain metabolism is the driving force behind MedDay. With the acquisition of Profilomic, we have significantly expanded our research capabilities and are excited to expand our pipeline. We fully intend to identify more opportunities to expand further and will continue to invest in our pipeline through future corporate developments.”

 

"MedDay is moving towards its goal of building a fully integrated biotechnology company, operating from discovery through to commercialization.”

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.